ADMS News and Press, Adamas Pharmaceuticals Inc. From 09/15/19

Bellus Health ( BLUSF ) could have its shares soon trading on the NASDAQ exchange. This is a very favourable announcement. As a result, we believe that market liquidity will increase, which may push the share price of Bellus up. We are positive on the stock. Another stock catalyst, which may e...

Adamas Pharmaceuticals (NASDAQ: ADMS ) appoints  Neil McFarlane as CEO and the member of Board of Directors, effective September 16, 2019. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

- Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceuti...

Adamas Pharmaceuticals (NASDAQ: ADMS ) initiated with Neutral rating and $8 (50% upside) price target at Cantor Fitzgerald. More news on: Adamas Pharmaceuticals, Inc., Covetrus, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...

Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...

More than a year ago, we wrote a series of articles on Adamas Pharmaceuticals ( ADMS ); in one of these, we said that ADMS is not a one-trick pony and that Gocovri's eventual label expansion in walking impairment in MS patients will be a far bigger revenue-generator than its existing approva...

Adamas Pharmaceuticals ( ADMS ) recently announced their Q2 earnings report that disclosed that the company beat on GAAP EPS by $0.12, but missed by $0.11M on revenue. During the earnings call, the company publicized their two priorities for the remainder of 2019. One, driving towards th...

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Peter Vozzo - Westwicke Partners Gregory Went - Founder, Chairman and Chief Executive Officer Vijay Shreedhar - Chief Commercial Officer Alfred Merriweat...

Adamas Pharma (NASDAQ: ADMS ): Q2 GAAP EPS of -$0.90 beats by $0.12 . Revenue of $12.69M (+67.6% Y/Y) misses by $0.11M . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

- Second quarter GOCOVRI® product sales of $12.7 million; total prescriptions grew to approximately 6,160 - INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment completed, with topline results expected late Q4 2019...